GMMG-HD9

• Status: aktiv
• A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma
• Kurzinformation
• Ansprechpartner:
  Dr. Jan Schleicher
  Telefon: 0711 278-35622
  E-Mail: j.schleicher@klinikum-stuttgart.de
• Studienzentrale
  Telefon: 0711 278 54961, -54539
  E-Mail: scc-studienzentrale@klinikum-stuttgart.de